MEK and PI3K inhibition in solid tumors: rationale and evidence to date
about
The value of genomics in dissecting the RAS-network and in guiding therapeutics for RAS-driven cancersDevelopment of a RSK Inhibitor as a Novel Therapy for Triple-Negative Breast Cancer.Insights into significance of combined inhibition of MEK and m-TOR signalling output in KRAS mutant non-small-cell lung cancerEnhanced anti-tumour activity of the combination of the novel MEK inhibitor WX-554 and the novel PI3K inhibitor WX-037.Natural compounds targeting major cell signaling pathways: a novel paradigm for osteosarcoma therapy.Dual Inhibition of PI3K/AKT and MEK/ERK Pathways Induces Synergistic Antitumor Effects in Diffuse Intrinsic Pontine Glioma Cells.PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer.Emerging targeted therapies for melanoma.Silencing the roadblocks to effective triple-negative breast cancer treatments by siRNA nanoparticles.Pharmacotherapeutic Management of Pancreatic Ductal Adenocarcinoma: Current and Emerging Concepts.Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies.Overexpression of the human antigen R suppresses the immediate paradoxical proliferation of melanoma cell subpopulations in response to suboptimal BRAF inhibition.microRNA-143/145 loss induces Ras signaling to promote aggressive Pten-deficient basal-like breast cancer.Kinase interest you in treating incubated cocaine-craving? A hypothetical model for treatment intervention during protracted withdrawal from cocaine.Dual blockade of the lipid kinase PIP4Ks and mitotic pathways leads to cancer-selective lethality.A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer.The microtubule-associated protein PRC1 is a potential therapeutic target for lung cancer.Combined kinase inhibitors of MEK1/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancer.Src-mediated regulation of the PI3K pathway in advanced papillary and anaplastic thyroid cancer.Blockage of the mevalonate pathway overcomes the apoptotic resistance to MEK inhibitors with suppressing the activation of Akt in cancer cells.Emerging Therapies in the Management of Advanced-Stage Gastric CancerConcomitant targeting of the mTOR/MAPK pathways: novel therapeutic strategy in subsets of -altered non-small cell lung cancer
P2860
Q26747403-6A5B5A22-1EA1-4554-BD8F-55C4F4641B28Q30275521-B0AA9582-899A-43AB-94C7-461148989A5BQ37203121-E6F149C5-4F5D-4848-B324-ABB2DAD4DC5EQ37421296-82B8A24F-E847-44BF-A8F3-F5E16C998C56Q37569758-E203C547-687E-4DBF-B764-4FBB51090B3AQ37635839-E00B9B9F-9C64-464C-BF41-8ECC8C7405E6Q37655023-B79337D9-34BF-4293-9330-B89810D26AE6Q38826425-9A4EFA47-2ACC-4229-938C-63AE4EF03EF1Q39113994-BF9E9FFA-9C6C-42FE-ACA8-EF6E874EC08EQ39204274-7786F97B-EE86-4A1A-9939-79CDF7145BC9Q39390859-5AFD8439-469A-4409-AC64-BCDBE98B09A3Q40975802-9993D195-3CA7-410E-BD73-F4D5FC0AABD8Q41252362-E9932C85-74E1-485E-8E9D-FDB340D0B81FQ46314070-F2628411-C14E-4AEA-BC5E-831C2B3CF33AQ47114330-81624B7A-3254-44CA-BB19-3C48ADE9C3FFQ47130538-8631368F-82D3-4046-883B-A415EF231A2EQ50052935-2BFE2EE1-AC7D-4DF1-A140-B579741A26B9Q51012619-72BC44FD-0250-4A7A-AAA8-AE4CD87AEA88Q52730006-FA735506-FE62-42C5-A8C0-D3C1168BFF9BQ55335270-50EB8455-F07C-4F17-89B5-ADAEB70F336EQ57111080-56135BBF-93C2-42DE-8AFD-03CE30C5EB56Q58552976-525F99AF-0B69-4DEC-83B5-0E31302E03E7
P2860
MEK and PI3K inhibition in solid tumors: rationale and evidence to date
description
2015 nî lūn-bûn
@nan
2015 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
MEK and PI3K inhibition in solid tumors: rationale and evidence to date
@ast
MEK and PI3K inhibition in solid tumors: rationale and evidence to date
@en
MEK and PI3K inhibition in solid tumors: rationale and evidence to date
@nl
type
label
MEK and PI3K inhibition in solid tumors: rationale and evidence to date
@ast
MEK and PI3K inhibition in solid tumors: rationale and evidence to date
@en
MEK and PI3K inhibition in solid tumors: rationale and evidence to date
@nl
prefLabel
MEK and PI3K inhibition in solid tumors: rationale and evidence to date
@ast
MEK and PI3K inhibition in solid tumors: rationale and evidence to date
@en
MEK and PI3K inhibition in solid tumors: rationale and evidence to date
@nl
P2860
P3181
P356
P1476
MEK and PI3K inhibition in solid tumors: rationale and evidence to date
@en
P2093
J P Koivunen
P2860
P304
P3181
P356
10.1177/1758834015571111
P407
P577
2015-05-01T00:00:00Z